COQ8A共济失调的临床遗传、影像与分子特征:59例多中心研究
该多中心研究纳入59例COQ8A共济失调患者,分析基因型-表型关联、蛋白建模、突变体外分析、MRI标志、疾病进展及辅酶Q10反应。结果显示多数为错义变异,多系统受累在错义变异中更常见;小脑萎缩普遍存在;SARA年进展约0.45分;辅酶Q10治疗部分患者临床改善。
要点
- COQ8A共济失调为早发性多系统疾病,常见癫痫、认知障碍及运动障碍。
- 错义变异患者多系统受累比例高于双等位基因功能丧失变异(82-93% vs 53%,p=0.029)。
- 辅酶Q10治疗在部分患者中临床或定量评估可见改善。
核心结论
- 本研究深化了对COQ8A共济失调的认识,并为大规模自然史研究和治疗试验奠定基础。
研究设计与样本
- 多中心队列研究,纳入59例COQ8A患者,进行基因型-表型关联、3D蛋白建模、突变体外分析、MRI标志、疾病进展及辅酶Q10反应分析。
主要发现
- 59例患者(39例新发)携带44种致病性COQ8A变异(18种新发)。
- 错义变异在蛋白建模和体外分析中表现出多效性有害效应。
- 临床表现为可变的多系统早发性小脑共济失调,伴癫痫(32%)、认知障碍(49%)、运动不耐受(25%)及多动性运动障碍(41%)。
- MRI显示小脑萎缩普遍(100%),28%患者可见大脑萎缩或齿状核及脑桥T2高信号。
- 横断面(n=34)和纵向(n=7)评估一致显示轻至中度共济失调进展(SARA:0.45/年)。
关键数值与推荐
- 多系统受累在错义变异中比双等位基因功能丧失变异更常见(82-93% vs 53%;p=0.029)。
- SARA年进展率为0.45/年(横断面n=34,纵向n=7)。
- 辅酶Q10治疗后SARA变化为-0.81/年(纵向定量评估n=11)。
临床怎么用
- 对早发性小脑共济失调伴癫痫、认知障碍或运动障碍者,应考虑COQ8A相关疾病并进行基因检测。
- 辅酶Q10可作为部分COQ8A共济失调患者的治疗选择,但需个体化评估疗效。
局限性
- 纵向评估样本量较小(n=7),辅酶Q10反应数据有限。
- 研究为观察性多中心队列,治疗反应需随机对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To foster trial-readiness of coenzyme Q8A (COQ8A)-ataxia, we map the clinicogenetic, molecular, and neuroimaging spectrum of COQ8A-ataxia in a large worldwide cohort, and provide first progression data, including treatment response to coenzyme Q10 (CoQ10). METHODS: Cross-modal analysis of a multicenter cohort of 59 COQ8A patients, including genotype-phenotype correlations, 3D-protein modeling, in vitro mutation analyses, magnetic resonance imaging (MRI) markers, disease progression, and CoQ10 response data. RESULTS: Fifty-nine patients (39 novel) with 44 pathogenic COQ8A variants (18 novel) were identified. Missense variants demonstrated a pleiotropic range of detrimental effects upon protein modeling and in vitro analysis of purified variants. COQ8A-ataxia presented as variable multisystemic, early-onset cerebellar ataxia, with complicating features ranging from epilepsy (32%) and cognitive impairment (49%) to exercise intolerance (25%) and hyperkinetic movement disorders (41%), including dystonia and myoclonus as presenting symptoms. Multisystemic involvement was more prevalent in missense than biallelic loss-of-function variants (82-93% vs 53%; p = 0.029). Cerebellar atrophy was universal on MRI (100%), with cerebral atrophy or dentate and pontine T2 hyperintensities observed in 28%. Cross-sectional (n = 34) and longitudinal (n = 7) assessments consistently indicated mild-to-moderate progression of ataxia (SARA: 0.45/year). CoQ10 treatment led to improvement by clinical report in 14 of 30 patients, and by quantitative longitudinal assessments in 8 of 11 patients (SARA: -0.81/year). Explorative sample size calculations indicate that ≥48 patients per arm may suffice to demonstrate efficacy for interventions that reduce progression by 50%. INTERPRETATION: This study provides a deeper understanding of the disease, and paves the way toward large-scale natural history studies and treatment trials in COQ8A-ataxia. ANN NEUROL 2020;88:251-263.
引用
- Traschütz A, Schirinzi T, Laugwitz L, et al. Clinico-Genetic, Imaging and Molecular Delineation of COQ8A-Ataxia: A Multicenter Study of 59 Patients. Ann Neurol. 2020. PMID: 32337771. doi:10.1002/ana.25751
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。